---
document_datetime: 2026-02-19 15:45:17
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/klisyri-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: klisyri-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.2230066
conversion_datetime: 2026-02-21 12:40:20.291534
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Klisyri

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a group of | 17/02/2026                          |                                             |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000323173   | variations.   |
|---------------------|---------------|

<div style=\"page-break-after: always\"></div>

| Renewal - 5 year / EMA/R/0000293300   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11/12/2025   | 12/02/2026   | SmPC, Annex II, Labelling and PL   |                   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|-------------------|
| Variation type IA_IN /                | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.a The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer - Accepted                                                                   | 29/09/2025   |              |                                    | EMA/VR/0000301552 |
| Variation type IB /                   | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted C.I.11.z (Type IB) - To postpone the due date of the interim results submission for the imposed (category 1) Post Authorisation Safety Study (PASS) M-14789-41 from Q4 2025 to Q2 2026. In addition, the post- authorization exposure numbers (Part II) and the QPPV name have been updated. | 26/08/2025   |              |                                    | EMA/VR/0000290392 |

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000262348   | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted   | 28/03/2025   |             |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------------|
| PSUR / EMA/PSUR/0000257888              |                                                                                                                                                                                                                                                                                                                                     |              | Maintenance |